HEALWELL AI’s Pentavere Achieves Validation of Generative AI for Preventative Care Through Landmark Publication

• Pentavere has published industry’s first peer-reviewed paper utilizing AI and large language models (or LLMs) to identify rare lung cancer patients.
  
• Industry applications may include Real World Evidence generation, identification of areas of unmet clinical need and optimization of cancer therapy and care pathways.
• Pentavere is an AI-powered patient identification company and this validated instance of identifying cancer patients using LLMs for preventative care purposes puts HEALWELL in a select group of companies globally with such capabilities.
  

TORONTO, April 04, 2024 (GLOBE NEWSWIRE) --  HEALWELL AI Inc. (“HEALWELL” or the “Company”) (TSX: AIDX) (OTCQX: HWAIF), an AI and data science company focused on preventative care, is pleased to announce its subsidiary Pentavere Research Group (“Pentavere”) has achieved a significant milestone with the publication of a paper validating the use of generative AI to identify rare lung cancer patients. The paper, titled "Real-world Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence"⁽¹⁾ marks an important moment in the application of AI in precision oncology. This landmark publication is industry’s first peer-reviewed paper utilizing AI and large language models to identify rare lung cancer patients using real world electronic health record data, supporting precision oncology efforts, and it showcases HEALWELL’s leadership position in developing AI technology applications in healthcare.

Aaron Leibtag, CEO of Pentavere, commented, “Pentavere is pushing the boundaries of innovation in healthcare and leveraging AI to address the most pressing challenges facing patients and healthcare providers. We have harnessed this capability into very productive work with world leading pharma and cancer centers to help optimize patient care in lung cancer. We’ve developed best in class AI that is core to our mission of preventative care. This paper highlights our ability to use generative AI in the real world to unlock key clinical and commercial value."

Dr. Alexander Dobranowski, CEO of HEALWELL, added, "We are immensely proud of the Pentavere team, and the innovative research showcased in this publication. This milestone validates the power of fine-tuned generative AI to drive meaningful insights and transform patient care. This pioneering research will set a new standard for the utilization of advanced technology in healthcare. We remain committed to leveraging AI to improve outcomes for patients worldwide.”